| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 29.09 | 0.84 (+2.97%) | 12.92 - 35.21 | 363.8 thousand (Below Avg) |
Market data as of 4:06PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 28.18 |
|---|---|
| Previous Close | 28.25 |
| Day's Range | 28.05 - 29.09 |
| Market Cap | 1.5B |
| Avg Volume (10 Day) | 422.8K |
| Price/Earnings (Trailing 12 Mo.) | 22.2x |
| Earnings Per Share (Trailing 12 Mo.) | 1.27 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Prestige Brands Holdings, Inc. Reports Record Fourth Quarter Revenues Up 15.3% and EPS of $0.37; Fiscal 13 Revenues Increase 41%; Reported EPS Up 74% to $1.27
Business Wire - Thursday 05/16/2013 6:00 AM ET
| PBH | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 41.38% | |
| Net Income Growth (1yr) | 76.03% | |
| Total Debt/Equity | 2.03 | |
| LT Debt/Equity | 2.03 | |
| Earnings Yield | 4.50% | |
| Price/Sales | 2.32 |
| Company | Last | Change |
|---|---|---|
| Impax Laboratories Inc | 18.80 | +1.08% |
| Aegerion Pharmaceuticals Inc | 60.09 | -1.43% |
| Pacira Pharmaceuticals Inc | 29.30 | -1.45% |
| BioScrip Inc | 13.48 | -0.88% |
| Neurocrine Biosciences Inc | 13.17 | +3.62% |
Data is delayed by at least 15 min.